EPS for Protagonist Therapeutics, Inc. (PTGX) Expected At $-0.24; 3 Analysts Are Bullish Premier African Minerals Limited (LON:PREM) Last Week

April 17, 2018 - By Marguerite Chambers

Premier African Minerals Limited (LON:PREM) Logo

Among 3 analysts covering Premier African Minerals (LON:PREM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Premier African Minerals had 95 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Corporate” rating by Northland Capital given on Monday, February 20. Northland Capital maintained the shares of PREM in report on Friday, July 1 with “Speculative Buy” rating. The stock has “Speculative Buy” rating by Beaufort Securities on Wednesday, May 3. The stock of Premier African Minerals Limited (LON:PREM) earned “Corporate” rating by Northland Capital on Tuesday, November 21. The company was maintained on Monday, March 27 by Shore Capital. The stock has “Speculative Buy” rating by Beaufort Securities on Monday, August 7. The stock of Premier African Minerals Limited (LON:PREM) earned “Speculative Buy” rating by Northland Capital on Thursday, December 14. The stock of Premier African Minerals Limited (LON:PREM) earned “Sell” rating by Beaufort Securities on Monday, August 10. The stock has “Corporate” rating by Northland Capital on Tuesday, February 28. The firm has “Speculative Buy” rating by Beaufort Securities given on Tuesday, March 21. See Premier African Minerals Limited (LON:PREM) latest ratings:

10/04/2018 Broker: Northland Capital Rating: Speculative Buy Maintain
02/02/2018 Broker: Northland Capital Rating: Speculative Buy Maintain
02/02/2018 Broker: Beaufort Securities Rating: Speculative Buy Maintain
16/01/2018 Broker: Northland Capital Rating: Speculative Buy Maintain
05/01/2018 Broker: Northland Capital Rating: Speculative Buy Maintain
05/01/2018 Broker: Beaufort Securities Rating: Speculative Buy Maintain
14/12/2017 Broker: Northland Capital Rating: Speculative Buy Maintain
14/12/2017 Broker: Beaufort Securities Rating: Speculative Buy Maintain
21/11/2017 Broker: Northland Capital Rating: Corporate Maintain
03/11/2017 Broker: Northland Capital Rating: Corporate Maintain

Analysts expect Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to report $-0.24 EPS on May, 9.They anticipate $0.60 EPS change or 71.43% from last quarter’s $-0.84 EPS. After having $-0.15 EPS previously, Protagonist Therapeutics, Inc.’s analysts see 60.00% EPS growth. The stock increased 1.74% or $0.155 during the last trading session, reaching $9.085. About 118,840 shares traded. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has declined 34.14% since April 17, 2017 and is downtrending. It has underperformed by 45.69% the S&P500.

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide chemical entities to address various unmet medical needs. The company has market cap of $191.73 million. It primarily focuses on developing oral peptide drugs. It currently has negative earnings. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin-specific antagonist that is in phase II clinical trial for the treatment of inflammatory bowel disease ; and PTG-200, an interleukin-23 receptor specific antagonist, which is under pre-clinical development stage for the treatment of IBD.

Premier African Minerals Limited, together with its subsidiaries, engages in the mining, exploration, evaluation, development, and investment of natural resource properties on the African continent. The company has market cap of 11.09 million GBP. The firm explores for tungsten, lithium, tantalum, fluorspar, phosphate, nickel, limestone, specialty minerals, and rare earth metals. It currently has negative earnings. The Company’s flagship project is the RHA Tungsten Mine located in Zimbabwe.

The stock decreased 1.52% or GBX 0.0025 during the last trading session, reaching GBX 0.1625. About 51.20M shares traded. Premier African Minerals Limited (LON:PREM) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>